請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/55864完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 胡務亮(Wuh-Liang Hwu,) | |
| dc.contributor.author | Li-Lan Liu | en |
| dc.contributor.author | 劉麗蘭 | zh_TW |
| dc.date.accessioned | 2021-06-16T05:09:45Z | - |
| dc.date.available | 2017-10-09 | |
| dc.date.copyright | 2014-10-09 | |
| dc.date.issued | 2014 | |
| dc.date.submitted | 2014-08-19 | |
| dc.identifier.citation | 1. 臨床生物化學,何敏夫著,合記出版社: 2007; 387-425.
2. 臨床生物化學,A+醫學百科. 3. Ana Maria, Teixeira, Grasiely F. Borges. Creatine Kinase: structure and function. Brazilian Journal of Biomotricity, 2012 ;62: 53-65. 4. Munsat TL, Balch R, Pearson CM, Fowler W. Serum enzyme alterations in neuromuscular disorders.J Am Med Assoc 173; 226: 1536-1543. 5. Duma RJ, SiegaI AL. Serum creatine phosphokinase in acute myocardial infarctions: diagnostic value.Arch Intern Med 1965; 115: 443-451. 6. Adam P. Orfanos and Edwin W. Naylor. A rapid screening test for Duchenne muscular dystrophy using dried blood specimens, Clinica Chimica Acta, 138 (1984) 261-274. 7. Dubowitz V. Screening for Duchenne muscular dystrophy. Arch Dis Child 1976; 51: 249-251. 8. Emery AEH. Duchenne muscular dystrophy. Genetics aspects, carrier detection and antenatal diagnosis. Br Med Bull 1980; 36: 117-122. 9. Moss DW, Whitaker KB, Parmar C et al. Activity of creatine kinase in sera from healthy women,carriers of Duchenne muscular dystrophy and cord blood, determined by ‘European’ recommended method with NAC-EDTA activation. CIin Chim Acta 1981; 116: 209-216. 10. 裘馨氏肌肉失養症 台大醫院基因醫學部[罕見疾病一點通]. 11. 裘馨氏肌肉失養症 財團法人罕見疾病基金會. 12. 裘馨氏肌肉失養症 衛生福利部國民健康署遺傳疾病諮詢 13. Website of Gene Reviews : Duchenne and Becker muscular dystrophy 14. 貝克型肌肉失養症 台大醫院基因醫學部[罕見疾病一點通]. 15. 貝克氏肌肉萎縮症-財團法人罕見疾病基金會/台大醫院基因醫學部. 16. Website of Genetics home reference : Duchenne and Becker muscular dystrophy 17. 龐貝氏症 台大醫院基因醫學部[罕見疾病一點通]. 18. Website of Gene Reviews: Limb-Girdle muscular dystrophy 19. 肢帶型肌肉萎縮症症 台大醫院基因醫學部[罕見疾病一點通]. 20. Website of Genetics home reference:Limb-Girdle muscular dystrophy. 21. Pearce JM, Pennington RJ, Walton JN. Serum enzyme studies in muscle disease. I. Variations in serum creatine kinase activity in normal individuals. J Neurol Neurosurg Psychiatry 1964; 27: 1–4. 22. Pearce JM, Pennington RJ, Walton JN. Serum enzyme studies in muscle disease. III. Serum creatine kinase activity in relatives of patients with Duchenne type muscular dystrophy. J Neurol Neurosurg Psychiatry 1964;27:181–185. 23. Wendy K. M. Liew and Peter B. Kang. Recent developments in the treatment of Duchenne muscular dystrophy and spinal muscular atrophy. Ther Adv Neurol Disord 2013; 63: 147–160. 24. 新生兒篩檢 財團法人罕見疾病基金會. 25. 新生兒篩檢 行政院衛生署國民健康局. 26. Zellweger H, Antonic A. Newborn screening for Duchenne muscular dystrophy. Pediatrics 1975; 55:30-34. 27. Drummond LM. Creatine phosphokinase levels in the newborn and their use in screening for Duchenne muscular dystrophy. Arch Dis Child 1979; 54: 362-366. 28. Skinner R, Emery AEH, Scheuerbrandt G, Syme J. Feasibility of neonatal screening for Duchenne muscular dystrophy. J Med Genet 1982; 19: 1-3. 29. Scheuerbrandt G, L?ovgren T, Mortier W. Screening for Duchenne muscular dystrophy: an improved screening test for creatine kinase and its application in an infant screening program. Muscle Nerve 1986; 9: 11-23. 30. Greenberg CR, Jacobs HK, Nylen E, et al. Gene studies in newborn males with Duchenne muscular dystrophy detected by neonatal screening. Lancet 1988; 2: 425-427. 31. Plauchu H, Dorche C, Cordier MP, et al. Duchenne muscular dystrophy: neonatal screening and prenatal diagnosis. Lancet 1989; 1: 669. 32. Naylor EW. New technologies in newborn screening. Yale J Biol Med 1991; 64:21-24. 33. Bradley DM, Parsons EP, Clarke AJ. Experience with screening newborns for Duchenne muscular dystrophy in Wales. BMJ 1993; 306: 357-360. 34. Drousiotou A, Ioannou P, Georgiou T, et al. Neonatal screening for Duchenne muscular dystrophy: a novel semiquantitative application of bioluminescence test for creatine kinase in a pilot national program in Cyprus. Genet Test 1998; 2: 55-60. 35. Eyskens F, Philips E. Newborn screening for Duchenne muscular dystrophy. The experience in the province of Antwerp. Neuromuscul Disord 2006; 16: 721. 36. Goemans NM, Tulinius M, van den Akker JT, et al. Systemic administration of PRO051 in Duchenne muscular dystrophy. N Engl J Med 2011; 364: 1513-1522. 37. Balaban B, Matthews DJ, Clayton GH, Carry T. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect. Am J Phys Med Rehabil 2005; 84: 843-850. 38. Moxley RT III, Pandya S, Ciafaloni E, et al. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol 2010; 25: 1116-1129 39. Jerry R. Mendell, MD, Chris Shilling, MS,1Nancy D. Leslie, MD, Kevin M. Flanigan, MD, Evidence-Based Path to Newborn Screening for Duchenne Muscular Dystrophy , American Neurological Association 2012; 304-313 40. RosaIki SB. An improved procedure for serum creatine phosphokinase determination. J Lab Clin Med 1967; 69: 696-706. 41. Hørder M, Magid E, Pitkänen E, Härkönen M, Strömme JH, Theodorsen L, Gerhardt W, Waldenström J . The Committee on Enzymes of the Scandinavian Society by Clinical Chemistry and Clinical Physiology: Recommended method for the determination of creatine kinase in blood modified by the inclusion of EDTA. Stand J Chn Lab Invest 1979; 39: l-5. 42. .Konttnen A, Somer H. Determination of serum creatine kinase isoenzymes in myocardial infarction. Am J Cardiol 1972; 29: 817-820. 43. Mercer DW. Separation of tissue and serum creatine kinase isoenzymes by ion-exchange column chromatography. CIin Chem 1974; 20: 36-40. 44. Morin LG. Evaluation of current methods for creatine kinase isoenzyme fractionation. Clin Chem 1977; 23: 205-210. 45. Skinner R, Emery AEH, Scheuerbrandt G, Syme J. Feasibility of neonatal screening for Duchenne muscular dystrophy. J Med Genet 1982; 19: 1–3. 46. Madhuri R. Hegde,_ Ephrem L.H. Chin, Jennifer G. Mulle, David T. Okou, Stephen T. Warren,and Michael E. Zwick. Microarray-Based Mutation Detection in the dystrophin Gene.,human mutation 2008; 1-9. 47. Greenberg CR, Jacobs HK, Nylen E, et al. Gene studies in newborn males with Duchenne muscular dystrophy detected by neonatal screening. Lancet 1988; 2: 425–427. 48. Byung Chan Lim, Seungbok Lee, Jong-Yeon Shin, Jong-Il Kim, Genetic Diagnosis of Duchenne and Becker Muscular Dystrophy Using Next-generation Sequencing Technology, J Med Genet. 2011; 48: 731-736. 49. Jerry R. Mendell, M.D., Louise Rodino-Klapac, Ph.D., Zarife Sahenk, M.D., Ph.D, Gene Therapy for Muscular Dystrophy: Lessons Learned and Path Forward , Neurosci Lett. Author manuscript; 2013 Oct 50. Walker HK, Hall WD, Hurst JW, editors. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd edition. 1990; Chapter 32 Creatine Kinase, 161-163 51. Plauchu H, Dorche C, Cordier MP, et al. Duchenne muscular dystrophy: neonatal screening and prenatal diagnosis. Lancet 1989; 1: 669. 52. Plauchu H, Dellamonica C, Cotte J, Robert JM. Duchenne muscular dystrophy: systematic neonatal screening and earlier detection of carriers. J Genet Hum 1980; 28: 65-82. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/55864 | - |
| dc.description.abstract | 背景
肌酸激酶(Creatine kinase, CK)是參與體內能量代謝的一種酵素,也是一種可逆磷酸化的酶,CK可形成高能量的三磷酸腺苷ATP,CK亦能供給肌肉能量的來源。在臨床上,測定血清CK檢查指的是血清中total CK的活性,由於在骨骼肌,心臟肌肉,和腦組織中含有豐富的激酸激酶。因此常用於肌肉相關疾病的檢查,如急性心肌梗塞,當這些部位受傷,血清中的CK會上升。在龐貝氏症、肢帶型肌肉失養症、心肌梗塞患者及肌營養不良症(如裘馨氏肌營養不良症及貝克型肌肉營養不良症)的血清中CK活性均呈現輕度至中度升高。而和CK的相關研究也顯示在裘馨氏肌肉失養症的男性患者CK活性會顯著升高,女性患者的CK活性則會輕微升高。 方法 本研究方法是利用血片檢體,做大規模的篩檢,以免疫螢光法檢測儀檢測血片中肌酸激酶的活性。 結果 本實驗總共分析有8,083個新生兒血片,其中男性有4,178個(51.7 %),女性有3,905個(48.3%),男女比例為1.07,在8,083個檢體中,CK值在1500 Flu/min以上共有10個檢體,佔0.12%,其中男性檢體有5人,女性檢體有5人,CK值在1,200至1,500 Flu/min有12個檢體,佔0.15%,男性檢體有7人,女性檢體有5人,CK值在1,000至1,200 Flu/min有23個檢體,佔0.28%,男性檢體有19人,女性檢體有4人。 結論 CK是一種來自肌肉的酵素,因此在肌肉受傷時,會引起CK的上升,本實驗方法是利用新生兒篩檢血片進行大量、快速,且有效的CK活性篩檢,找出高CK疑陽性個案。我們的研究結果,CK Flu/min >= 1,000共計有45個檢體為高疑陽性個案。在CK與其他因子的關連性研究的結果顯示,在CK與性別的關連性上,其在統計上沒有顯著差異(P > 0.05)。在CK與出生體重的關連性上,以體重小於或大於等於2,200 g做分組研究,在統計上具有顯著差異(P < 0.05)。在CK與妊娠週數的關連性上,以妊娠週數小於或大於等於37週做分組研究,在統計上具有顯著差異(P < 0.05)。在CK與CAH的關連性上,以妊娠週數大於等於37週做分組研究,統計上具有顯著差異(P < 0.05)。CK活性的確有可能因生產過程的擠壓而略為升高,但應該不會影響高疑陽性個案的判斷。在CK與性G6PD的關連性上,結果顯示G6PD缺乏症患者的CK數值並不會有偏低之情形發生。G6PD缺乏症應該不會影響CK反應下降,造成偽陰性的判斷。 | zh_TW |
| dc.description.abstract | Background
Creatine kinase, a reversible phosphorylation enzyme, is one of the enzymes involved in energy metabolism. It can form a high energy triphosphate ATP and provide the muscle energy. Clinically, serum CK examination refers to the total CK activity in serum. Due to the significant amount of kinase in skeletal and heart muscle, and brain.CK is commonly used as an indicator to examine the muscle-related disorders. When injuries of muscle, brain and heart occur, the CK level is usually elevated. In most patients with Pompe disease, limb-girdle muscular dystrophy, myocardial infarction, and muscular dystrophy (such as Duchenne muscular dystrophy and Becker muscular dystrophy), CK activity also showed mild to moderate elevations. In the cases of Duchenne muscular dystrophy, the serum CK activity is significantly increased in male patients but only slightly elevated in female patients. Method Our research method use the dried blood spot samples for mass screening to detect creatine kinase activity by fluorescence detector . Results In this study, a total of 8,083 newborns dried blood spots were analyzed. Among them, there were 4,178 male (51.7%) and 3,905 female (48.3%), and the male to female ratio was 1.07. The CK Flu / min values greater than 1,500 or more was detected in 10 cases (0.12%) of which male vs. females were equal. The CK Flu / min values of 1,200-1,500 was found in 12 samples (0.15%)indicated 7 male and 5 female subjects. The CK Flu / min values in 1,000-1,200 was detected in 23 samples (0.28%) 19 male and 4 female subjects. Conclusions Clinically, CK is commonly used as an indicator to examine the muscle-related disorders. In this study, we perform a rapid and effective high-through put screening using the newborn screening dried blood spots. From the results, there are 45 cases with higher CK activity (>=1,000 CK Flu/min) in the DBS. In the study of CK and other parameters, we find no relation between CK and Gender, but there are relationship between CK & Birth weight and CK & Gestational age. From the CK and CAH study, birth Stress may certainly make some raise in the CK level, but it may not influence the judgement of hyper-creatine kinase-emia. Although we use the reagents with G6PD enzyme, the G6PD enzyme deficiency in the DBS may not decrease the CK reaction obviously. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-16T05:09:45Z (GMT). No. of bitstreams: 1 ntu-103-P01448008-1.pdf: 3532593 bytes, checksum: a547eef34cf12c1feb310847cb69ab5a (MD5) Previous issue date: 2014 | en |
| dc.description.tableofcontents | 口試委員審定書 I
誌謝 II 中文摘要 IX Abstract XI 第一章、緒論 1 第一節 肌酸激酶 1 第二節 裘馨氏肌肉失養症與肌肉疾病 3 1. 裘馨氏肌肉失養症與貝克型肌肉失養症 3 2. 裘馨氏肌肉失養症與貝克型肌肉失養症的臨床症狀 4 3. 其他肌肉疾病 5 4. 肌酸激酶與肌肉疾病 6 第三節 新生兒篩檢 7 第二章、研究動機與目的 9 第一節 研究動機 9 第二節 研究目的 10 第三章、實驗方法與原理 11 第一節 實驗設計 11 第二節 實驗原理 14 第三節 實驗方法 16 第四章、結果 17 第一節 標準曲線(Standard curve)之計算 17 第二節 新生兒篩檢血片CK活性之計算 18 第三節 Control血片之穩定度 19 第四節 新生兒篩檢血片CK數值的分佈 20 第五節 Cut-off及重新檢驗的標準之訂定 21 第六節 新生兒篩檢血片結果之CK數值分析 22 第七節 CK與其他因子的關連性 23 第五章、討論 26 第一節 本實驗方法之優點 26 第二節 本實驗方法之干擾因子 27 第三節 CK與其他相關因子 28 第四節 實驗方法之相關文獻比較 30 第五節 CK血片篩檢的適用性與適用性 33 第六節 新生兒篩檢裘馨氏肌肉失養症的可行性 34 第七節 高CK之臨床應用 35 第八節 本實驗方法之未來發展 36 第六章、結論 37 參考文獻 38 附錄 43 | |
| dc.language.iso | zh-TW | |
| dc.subject | 肌酸激? | zh_TW |
| dc.subject | 裘馨氏肌肉失養症 | zh_TW |
| dc.subject | 代謝性肌肉疾病 | zh_TW |
| dc.subject | 新生兒篩檢 | zh_TW |
| dc.subject | 乾燥血片 | zh_TW |
| dc.subject | Creatine kinase | en |
| dc.subject | Duchenne Muscular Dystrophy | en |
| dc.subject | Metabolic muscular disease | en |
| dc.subject | newborn screen | en |
| dc.subject | Dried blood spot | en |
| dc.title | 高肌酸激酶血症新生兒篩檢技術之開發 | zh_TW |
| dc.title | Development of a newborn screening technique for hyper-creatine kinase-emia | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 102-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 簡穎秀(Yin-Hsiu, Chien),李妮鍾(Ni-Chung Lee) | |
| dc.subject.keyword | 肌酸激?,裘馨氏肌肉失養症,代謝性肌肉疾病,新生兒篩檢,乾燥血片, | zh_TW |
| dc.subject.keyword | Creatine kinase,Duchenne Muscular Dystrophy,Metabolic muscular disease,newborn screen,Dried blood spot, | en |
| dc.relation.page | 64 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2014-08-19 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 分子醫學研究所 | zh_TW |
| 顯示於系所單位: | 分子醫學研究所 | |
文件中的檔案:
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-103-1.pdf 未授權公開取用 | 3.45 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。
